Syngene International Limited is one of the largest and fastest growing global Contract Research Organisations (CRO), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (“NMEs”) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. We have the financial stability and steady operational cash flows to enable the extension of our platforms in line with the present and future needs of our clientele. Our long-term collaborations ensures predictable and stable cash flows. Our strong balance sheet and financial performance has helped us in reassuring clients that we will be able to support their NME development with dedicated investments in terms of both capabilities and capacities. Over the years, we have invested in specialised services and equipment and dedicated infrastructure to support these growing needs. Our ability to make these investments helps strengthen trust and engagement with our clients, which enhances our ability to retain them and extend our engagement across multiple platforms.
For the latest annual report click: Annual Report 2017-18
For AGM notice click: AGM Notice 2018